anti-BCMA STAb-T cells

Anti-BCMA STAb-T cells are genetically engineered T lymphocytes designed to **secrete bispecific T cell engager antibodies** that target both B cell maturation antigen (BCMA) on malignant plasma cells and CD3 on endogenous T cells. Unlike CAR-T cells, which express chimeric antigen receptors, STAb-T cells actively secrete these bispecific antibodies into the tumor microenvironment. This approach enables direct targeting and killing of BCMA-expressing multiple myeloma cells, recruitment and activation of bystander T cells, and the formation of durable immunological memory. Notably, anti-BCMA STAb-T cells are resistant to inhibition by soluble BCMA, a mechanism of resistance in some relapsed/refractory multiple myeloma patients, and have demonstrated superior preclinical efficacy compared to conventional CAR-T cells in murine models. This therapy is under preclinical development for **multiple myeloma** and potentially other BCMA-expressing hematologic malignancies[1][2][5][6].

Other names

BCMA STAb-T cellsBCMA TCE-secreting T cellsBCMA T cell engagersSTAb-T cells